357 related articles for article (PubMed ID: 19515851)
1. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43.
Nonaka T; Kametani F; Arai T; Akiyama H; Hasegawa M
Hum Mol Genet; 2009 Sep; 18(18):3353-64. PubMed ID: 19515851
[TBL] [Abstract][Full Text] [Related]
2. [The molecular mechanisms of intracellular TDP-43 aggregates].
Nonaka T; Arai T; Hasegawa M
Brain Nerve; 2009 Nov; 61(11):1292-300. PubMed ID: 19938686
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy.
Arai T; Hasegawa M; Nonoka T; Kametani F; Yamashita M; Hosokawa M; Niizato K; Tsuchiya K; Kobayashi Z; Ikeda K; Yoshida M; Onaya M; Fujishiro H; Akiyama H
Neuropathology; 2010 Apr; 30(2):170-81. PubMed ID: 20102522
[TBL] [Abstract][Full Text] [Related]
4. [Intracellular seeded aggregation of TDP-43].
Nonaka T; Hasegawa M
Rinsho Shinkeigaku; 2012; 52(11):1056-8. PubMed ID: 23196514
[TBL] [Abstract][Full Text] [Related]
5. [TDP-43 proteinopathies, toward understanding of the molecular pathogenesis].
Hasegawa M; Nonaka T; Yamashita M; Kametani F; Arai T; Yoshida M; Hashizume Y; Tsuchiya K; Akiyama H
Rinsho Shinkeigaku; 2009 Nov; 49(11):783-5. PubMed ID: 20030209
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells.
Nonaka T; Arai T; Buratti E; Baralle FE; Akiyama H; Hasegawa M
FEBS Lett; 2009 Jan; 583(2):394-400. PubMed ID: 19111550
[TBL] [Abstract][Full Text] [Related]
7. [Neurodegenerative disorders and TDP-43].
Nonaka T; Inukai Y; Arai T; Hasegawa M
Brain Nerve; 2009 Feb; 61(2):161-6. PubMed ID: 19235466
[TBL] [Abstract][Full Text] [Related]
8. [Molecular dissection of TDP-43 in ALS and FTLD].
Hasegawa M; Arai T; Nonaka T; Tsuji H; Yamashita M; Hosokawa M; Kametani F; Tamaoka A; Akiyama H
Rinsho Shinkeigaku; 2010 Nov; 50(11):937-9. PubMed ID: 21921518
[TBL] [Abstract][Full Text] [Related]
9. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity.
Zhang YJ; Xu YF; Cook C; Gendron TF; Roettges P; Link CD; Lin WL; Tong J; Castanedes-Casey M; Ash P; Gass J; Rangachari V; Buratti E; Baralle F; Golde TE; Dickson DW; Petrucelli L
Proc Natl Acad Sci U S A; 2009 May; 106(18):7607-12. PubMed ID: 19383787
[TBL] [Abstract][Full Text] [Related]
10. Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies.
Igaz LM; Kwong LK; Chen-Plotkin A; Winton MJ; Unger TL; Xu Y; Neumann M; Trojanowski JQ; Lee VM
J Biol Chem; 2009 Mar; 284(13):8516-24. PubMed ID: 19164285
[TBL] [Abstract][Full Text] [Related]
11. Inositol Hexakisphosphate Kinase 2 Promotes Cell Death in Cells with Cytoplasmic TDP-43 Aggregation.
Nagata E; Nonaka T; Moriya Y; Fujii N; Okada Y; Tsukamoto H; Itoh J; Okada C; Satoh T; Arai T; Hasegawa M; Takizawa S
Mol Neurobiol; 2016 Oct; 53(8):5377-83. PubMed ID: 26440668
[TBL] [Abstract][Full Text] [Related]
12. [Significance of the TDP-43 deposition in FTLD-U and ALS].
Hasegawa M; Arai T; Nonaka T; Kametani F; Yoshida M; Hashizume Y; Beach TG; Morita M; Nakano I; Oda T; Tsuchiya K; Akiyama H
Rinsho Shinkeigaku; 2008 Nov; 48(11):994-7. PubMed ID: 19198142
[TBL] [Abstract][Full Text] [Related]
13. TDP-43 dimerizes in human cells in culture.
Shiina Y; Arima K; Tabunoki H; Satoh J
Cell Mol Neurobiol; 2010 May; 30(4):641-52. PubMed ID: 20043239
[TBL] [Abstract][Full Text] [Related]
14. Aggregation of the 35-kDa fragment of TDP-43 causes formation of cytoplasmic inclusions and alteration of RNA processing.
Che MX; Jiang YJ; Xie YY; Jiang LL; Hu HY
FASEB J; 2011 Jul; 25(7):2344-53. PubMed ID: 21450909
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
Hasegawa M; Arai T; Nonaka T; Kametani F; Yoshida M; Hashizume Y; Beach TG; Buratti E; Baralle F; Morita M; Nakano I; Oda T; Tsuchiya K; Akiyama H
Ann Neurol; 2008 Jul; 64(1):60-70. PubMed ID: 18546284
[TBL] [Abstract][Full Text] [Related]
16. [A new dementia group caused by TDP-43 abnormality].
Arai T; Hosokawa M; Hasegawa M; Akiyama H; Asada T
Seishin Shinkeigaku Zasshi; 2011; 113(6):574-83. PubMed ID: 21815469
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin.
Dormann D; Capell A; Carlson AM; Shankaran SS; Rodde R; Neumann M; Kremmer E; Matsuwaki T; Yamanouchi K; Nishihara M; Haass C
J Neurochem; 2009 Aug; 110(3):1082-94. PubMed ID: 19522733
[TBL] [Abstract][Full Text] [Related]
18. C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation.
Josephs KA; Zhang YJ; Baker M; Rademakers R; Petrucelli L; Dickson DW
Acta Neuropathol Commun; 2019 Jul; 7(1):100. PubMed ID: 31266542
[TBL] [Abstract][Full Text] [Related]
19. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
Arai T; Hasegawa M; Akiyama H; Ikeda K; Nonaka T; Mori H; Mann D; Tsuchiya K; Yoshida M; Hashizume Y; Oda T
Biochem Biophys Res Commun; 2006 Dec; 351(3):602-11. PubMed ID: 17084815
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated TDP-43 becomes resistant to cleavage by calpain: A regulatory role for phosphorylation in TDP-43 pathology of ALS/FTLD.
Yamashita T; Teramoto S; Kwak S
Neurosci Res; 2016 Jun; 107():63-9. PubMed ID: 26723245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
